SBFM Sunshine Biopharma Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1402328 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-5.2%
TTM net income YoY-3.0%
TTM EPS YoY—
Revenue 3-yr CAGR20.2%
Net income 3-yr CAGR—
Margins
Gross margin30.4%
Operating margin-17.2%
Net margin-17.5%
FCF margin—
EBITDA margin-16.3%
Returns
ROE-23.4%
ROA-18.9%
ROIC (approx.)-33.3%
Asset turnover1.08x
Leverage & solvency
Liabilities / assets15.4%
Debt / equity0.00x
Current ratio6.47x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.97x
Accruals ratio-0.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $9.44M | $9.26M | $8.09M | $8.58M | $9.42M | $9.41M | $8.90M | $9.59M |
| Cost of revenue | $6.34M | $6.84M | $5.91M | $5.55M | $6.34M | $5.99M | $6.17M | $6.50M |
| Gross profit | $3.10M | $2.43M | $2.18M | $3.03M | $3.07M | $3.42M | $2.73M | $3.09M |
| R&D expense | $1,563 | $13,222 | $31,724 | $73,501 | $119,298 | $196,232 | $215,277 | $149,272 |
| SG&A expense | $4.39M | $4.04M | $3.58M | $4.82M | $4.16M | $5.48M | $4.03M | $5.13M |
| Operating income | -$1.29M | -$1.61M | -$1.40M | -$1.79M | -$1.09M | -$2.05M | -$1.30M | -$2.04M |
| Interest expense | — | — | — | $0 | $0 | $0 | $0 | $8,529 |
| Pretax income | -$1.29M | -$1.56M | -$1.24M | -$1.73M | -$1.02M | -$1.98M | -$1.22M | -$2.29M |
| Income tax | -$63,538 | $0 | $0 | $408,374 | -$137,438 | -$209,166 | -$40,161 | -$128,737 |
| Net income | -$1.22M | -$1.56M | -$1.24M | -$2.14M | -$883,820 | -$1.77M | -$1.18M | -$2.16M |
| EBITDA | -$1.22M | -$1.53M | -$1.32M | -$1.69M | -$990,792 | -$1.98M | -$1.23M | -$1.97M |
| EPS (basic) | -5.20 | -1.15 | -0.25 | — | -38.80 | -3.94 | -0.44 | — |
| EPS (diluted) | — | — | — | — | — | -0.82 | -0.44 | — |
| Weighted avg. shares (diluted) | — | — | — | — | — | 3.60M | 2.70M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $14.62M | $13.75M | $6.91M | $9.12M | $9.31M | $10.31M | $8.12M | $9.69M |
| Receivables | $3.89M | $4.04M | $4.01M | $3.46M | $4.16M | $3.59M | $3.45M | $3.87M |
| Inventory | $11.66M | $12.12M | $13.17M | $13.47M | $14.06M | $13.02M | $11.86M | $11.28M |
| Current assets | $31.00M | $30.67M | $24.78M | $26.85M | $27.97M | $27.85M | $24.48M | $25.97M |
| PP&E, net | $361,916 | $477,047 | $516,349 | $557,370 | $598,087 | $638,354 | $519,787 | $546,055 |
| Goodwill | — | — | — | — | — | — | — | $0 |
| Intangibles | $1.89M | $1.84M | $1.92M | $1.89M | $2.01M | $2.49M | $3.19M | $3.02M |
| Total assets | $33.86M | $33.63M | $27.93M | $30.08M | $31.49M | $31.97M | $29.19M | $30.56M |
| Current liabilities | $4.79M | $5.62M | $5.88M | $6.44M | $6.65M | $5.57M | $5.76M | $6.31M |
| Total liabilities | $5.22M | $6.09M | $6.41M | $7.04M | $7.29M | $6.28M | $6.48M | $7.06M |
| Shareholders' equity | $28.64M | $27.54M | $21.52M | $23.04M | $24.20M | $25.68M | $22.70M | $23.50M |
| Shares outstanding | 278,317 | 2.39M | 4.91M | 24,530 | 4.56M | 4.56M | 2.71M | 2.58M |
| Cash flow statement | ||||||||
| Operating cash flow | -$1.38M | -$917,977 | -$2.07M | -$1.62M | -$747,009 | -$1.27M | -$1.70M | -$3.41M |
| Capital expenditure | — | $7,015 | $5,129 | -$1,039 | $8,040 | $160,000 | $7,490 | $102,600 |
| Free cash flow | — | -$924,992 | -$2.08M | -$1.61M | -$755,049 | -$1.43M | -$1.70M | -$3.51M |
| Investing cash flow | $25,362 | -$5,120 | -$104,518 | -$50,209 | -$118,295 | -$550,187 | -$212,017 | -$97,770 |
| Financing cash flow | $2.23M | $7.80M | $0 | $724,500 | $75,536 | $3.67M | $355,297 | $1.62M |
| Depreciation & amortization | $74,609 | $77,974 | $76,859 | $98,923 | $95,821 | $72,533 | $64,793 | $65,399 |
| Share buybacks | — | — | — | $0 | $0 | $0 | $0 | $0 |
Free plan shows the latest 8 periods; Pro shows all 68 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.